Details of Drug

Drug General Information (ID: D0608)
Drug Name	Estramustine
Drug Type	Small molecule
Drug Synonymous	Estramustina; Estramustinum; Emcyt (TN); Estramustine (USAN/INN); Estradiol 3-[bis(2-chloroethyl)carbamate]; Ro-22-2296/000; Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-, 3-[bis(2-chloroethyl)carbamate]; [(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate; (17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl bis(2-chloroethyl)carbamate; 17.beta.-Estradiol 3-[bis(2-chloroethyl)carbamate] Click to Show/Hide
Disease Class	2C82: Prostate cancer
Therapeutic Class	Antineoplastics
Structure
Structure	3D Structure		2D Structure
Formula	C23H31Cl2NO3
InChI	1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1
InChIKey	FRPJXPJMRWBBIH-RBRWEJTLSA-N
Canonical SMILES	CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl
External Link
	Pubchem ID	259331
	CAS Number	2998-57-4
	CHEBI ID	4868
	TTD ID	D03SRY
	INTEDE ID	DR0645
	VARIDT ID	DR00522

Drug-Drug Interaction Network
Sunburst Graph		Legend Information AM003 Affected organization distribution AM004 Affected intra/extra-hepatic metabolism AM006 Pharmacodynamic additive effects AM007 Pharmacodynamic antagonistic effects BM015 Increase globulin concentration BM025 Decreased metabolism (Unspecific) BM043 Additive immunosuppressive effects BM047 Additive thrombogenic effects BM072 Increased risk of nephrotoxicity BM085 Antagonize the effect of antithrombotic agents BM086 Antagonize the effect of antidiabetic agents BM089 Antagonize the effect of antihypertensive agents BM107 Attenuated pharmacological effects (Unspecific) BM108 Increased risk of hypercalcemia
Relation Graph

Full list of drugs interacting with Estramustine
Affected organization distribution
	Increase globulin concentration					Drug Num: 16
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0172		Betamethasone	C22H29FO5	9782	Moderate		Inter Info	[15], [16], [17]
D0215		Budesonide	C25H34O6	5281004	Moderate		Inter Info	[15], [16], [17]
D0392		Corticotropin	C207H308N56O58S	16132265	Moderate		Inter Info	[15], [16], [17]
D0436		Deflazacort	C25H31NO6	189821	Moderate		Inter Info	[15], [16], [17]
D0453		Dexamethasone	C22H29FO5	5743	Moderate		Inter Info	[15], [16], [17]
D1563		Tetracosactide	C136H210N40O31S	16133802	Moderate		Inter Info	[15], [16], [17]
D1577		Thyroid, porcine	NA	NA	Moderate		Inter Info	[24], [25], [26]
D0671		Fludrocortisone	C21H29FO5	31378	Moderate		Inter Info	[15], [16], [17]
D0773		Hydrocortisone	C21H30O5	5754	Moderate		Inter Info	[15], [16], [17]
D0925		Levothyroxine	C15H11I4NO4	5819	Moderate		Inter Info	[24], [30], [31], [32], [25], [26]
D0934		Liothyronine	C15H12I3NO4	5920	Moderate		Inter Info	[24], [30], [31], [32], [25], [26]
D1041		Methylprednisolone	C22H30O5	6741	Moderate		Inter Info	[15], [16], [17]
D1332		Prednisolone	C21H28O5	5755	Moderate		Inter Info	[15], [16], [17]
D1334		Prednisone	C21H26O5	5865	Moderate		Inter Info	[15], [16], [17]
D1628		Triamcinolone	C21H27FO6	31307	Moderate		Inter Info	[15], [16], [17]
D1630		Triamcinolone (ophthalmic)	C21H27FO6	31307	Moderate		Inter Info	[15], [16], [17]
Affected intra/extra-hepatic metabolism
	Decreased metabolism (Unspecific)					Drug Num: 9
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0068		Amitriptyline	C20H23N	2160	Minor		Inter Info	[37], [38], [39]
D0072		Amoxapine	C17H16ClN3O	2170	Minor		Inter Info	[37], [38], [39]
D0446		Desipramine	C18H22N2	2995	Minor		Inter Info	[37], [38], [39]
D0525		Doxepin	C19H21NO	667477	Minor		Inter Info	[37], [38], [39]
D0361		Clomipramine	C19H23ClN2	2801	Minor		Inter Info	[37], [38], [39]
D0795		Imipramine	C19H24N2	3696	Minor		Inter Info	[37], [38], [39]
D1158		Nortriptyline	C19H21N	4543	Minor		Inter Info	[37], [38], [39]
D1361		Protriptyline	C19H21N	4976	Minor		Inter Info	[37], [38], [39]
D1647		Trimipramine	C20H26N2	5584	Minor		Inter Info	[37], [38], [39]
Pharmacodynamic additive effects
	Additive immunosuppressive effects					Drug Num: 1
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1174		Omacetaxine mepesuccinate	C29H39NO9	285033	Moderate		Inter Info	[23]
	Additive thrombogenic effects					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1569		Thalidomide	C13H10N2O4	5426	Major		Inter Info	[1], [2], [3]
D1619		Tranexamic acid	C8H15NO2	5526	Major		Inter Info	[4], [5], [6]
	Increased risk of nephrotoxicity					Drug Num: 5
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0075		Amphotericin B	C47H73NO17	5280965	Moderate		Inter Info	[10], [11]
D0076		Amphotericin B (cholesteryl sulfate)	C47H73NO17	5280965	Moderate		Inter Info	[10], [11]
D0078		Amphotericin B (liposomal)	C47H73NO17	5280965	Moderate		Inter Info	[10], [11]
D0724		Givosiran	C78H139N11O30	119058042	Moderate		Inter Info	[10], [11]
D1304		Plazomicin	C25H48N6O10	42613186	Moderate		Inter Info	[10], [11]
	Increased risk of hypercalcemia					Drug Num: 2
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1754		Calcitriol (topical)	C27H44O3	5280453	Moderate		Inter Info	[18], [19]
D1753		Calcipotriol (topical)	C27H40O3	5288783	Moderate		Inter Info	[18], [19]
Pharmacodynamic antagonistic effects
	Antagonize the effect of antithrombotic agents					Drug Num: 3
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0087		Anisindione	C16H12O3	2197	Moderate		Inter Info	[12], [13], [14]
D0481		Dicoumarol	C19H12O6	54676038	Moderate		Inter Info	[12], [13], [14]
D1711		Warfarin	C19H16O4	54678486	Moderate		Inter Info	[33], [34], [35], [12], [36], [13], [14]
	Antagonize the effect of antidiabetic agents					Drug Num: 40
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0009		Acarbose	C25H43NO18	41774	Moderate		Inter Info	[7], [8], [9]
D0013		Acetohexamide	C15H20N2O4S	1989	Moderate		Inter Info	[7], [8], [9]
D0325		Chlorpropamide	C10H13ClN2O3S	2727	Moderate		Inter Info	[7], [8], [9]
D0029		Albiglutide	C148H224N40O45	145994868	Moderate		Inter Info	[7], [8], [9]
D0042		Alogliptin	C18H21N5O2	11450633	Moderate		Inter Info	[7], [8], [9]
D0245		Canagliflozin	C24H25FO5S	24812758	Moderate		Inter Info	[7], [8], [9]
D0418		Dapagliflozin	C21H25ClO6	9887712	Moderate		Inter Info	[7], [8], [9]
D0565		Empagliflozin	C23H27ClO7	11949646	Moderate		Inter Info	[7], [8], [9]
D0807		Insulin aspart (aspart protamine)	C256H381N65O79S6	118984445	Moderate		Inter Info	[7], [8], [9]
D0808		Insulin aspart (aspart)	C256H381N65O79S6	118984445	Moderate		Inter Info	[7], [8], [9]
D0809		Insulin degludec	C274H411N65O81S6	118984462	Moderate		Inter Info	[7], [8], [9]
D0810		Insulin detemir	C267H402N64O76S6	16137271	Moderate		Inter Info	[7], [8], [9]
D0812		Insulin glulisine	C258H384N64O78S6	16136701	Moderate		Inter Info	[7], [8], [9]
D0930		Linagliptin	C25H28N8O2	10096344	Moderate		Inter Info	[7], [8], [9]
D0936		Liraglutide	C172H265N43O51	16134956	Moderate		Inter Info	[7], [8], [9]
D0941		Lixisenatide	C215H347N61O65S	90472060	Moderate		Inter Info	[7], [8], [9]
D1326		Pramlintide	C171H267N51O53S2	70691388	Moderate		Inter Info	[7], [8], [9]
D1449		Saxagliptin	C18H25N3O2	11243969	Moderate		Inter Info	[7], [8], [9]
D1477		Sitagliptin	C16H15F6N5O	4369359	Moderate		Inter Info	[7], [8], [9]
D0727		Glimepiride	C24H34N4O5S	3476	Moderate		Inter Info	[7], [8], [9]
D0728		Glipizide	C21H27N5O4S	3478	Moderate		Inter Info	[7], [8], [9]
D0730		Glyburide	C23H28ClN3O5S	3488	Moderate		Inter Info	[7], [8], [9]
D0811		Insulin glargine	C267H404N72O78S6	118984454	Moderate		Inter Info	[7], [8], [9]
D0813		Insulin human	C257H383N65O77S6	118984375	Moderate		Inter Info	[7], [8], [9]
D0814		Insulin human (inhalation, rapid acting)	C257H383N65O77S6	118984375	Moderate		Inter Info	[7], [8], [9]
D0815		Insulin human (isophane)	C257H383N65O77S6	118984375	Moderate		Inter Info	[7], [8], [9]
D0816		Insulin human (regular)	C257H383N65O77S6	118984375	Moderate		Inter Info	[7], [8], [9]
D0817		Insulin human (zinc extended)	C257H383N65O77S6	118984375	Moderate		Inter Info	[7], [8], [9]
D0818		Insulin human (zinc)	C257H383N65O77S6	118984375	Moderate		Inter Info	[7], [8], [9]
D0819		Insulin lispro	C257H389N65O77S6	16132438	Moderate		Inter Info	[7], [8], [9]
D0820		Insulin lispro (protamine)	C257H389N65O77S6	16132438	Moderate		Inter Info	[7], [8], [9]
D1015		Metformin	C4H11N5	4091	Moderate		Inter Info	[7], [8], [9]
D1064		Miglitol	C8H17NO5	441314	Moderate		Inter Info	[7], [8], [9]
D1112		Nateglinide	C19H27NO3	5311309	Moderate		Inter Info	[7], [8], [9]
D1294		Pioglitazone	C19H20N2O3S	4829	Moderate		Inter Info	[7], [8], [9]
D1392		Repaglinide	C27H36N2O4	65981	Moderate		Inter Info	[7], [8], [9]
D1429		Rosiglitazone	C18H19N3O3S	77999	Moderate		Inter Info	[7], [8], [9]
D1601		Tolazamide	C14H21N3O3S	5503	Moderate		Inter Info	[7], [8], [9]
D1603		Tolbutamide	C12H18N2O3S	5505	Moderate		Inter Info	[7], [8], [9]
D1652		Troglitazone	C24H27NO5S	5591	Moderate		Inter Info	[7], [8], [9]
	Antagonize the effect of antihypertensive agents					Drug Num: 4
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D1779		Dulaglutide	NA	NA	Moderate		Inter Info	[7], [8], [9]
D1782		Ertugliflozin	C22H25ClO7	44814423	Moderate		Inter Info	[7], [8], [9]
D1784		Exenatide	C184H282N50O60S	45588096	Moderate		Inter Info	[7], [8], [9]
D1887		Semaglutide	C187H291N45O59	56843331	Moderate		Inter Info	[7], [8], [9]
	Attenuated pharmacological effects (Unspecific)					Drug Num: 6
Drug ID		Drug Name	Formula	Pubchem ID	Severity Level		Interaction Detail	REF
D0086		Anastrozole	C17H19N5	2187	Moderate		Inter Info	[20], [21], [22]
D0630		Exemestane	C20H24O2	60198	Moderate		Inter Info	[20], [21], [22]
D0890		Lamotrigine	C9H7Cl2N5	3878	Moderate		Inter Info	[27], [28], [29]
D0907		Letrozole	C17H11N5	3902	Moderate		Inter Info	[20], [21], [22]
D1557		Testolactone	C19H24O3	13769	Moderate		Inter Info	[20], [21], [22]
D1812		Hyaluronidase	C17H24BrNO2	91820602	Minor		Inter Info	[40], [41], [42]

References
1	Figg WD, Arlen P, Gulley J, et al. "A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer." Semin Oncol 28(4 Suppl 15) (2001): 62-6. [PMID: 11685731]
2	Fine HA, Wen PY, Maher EA, et al. "Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas." J Clin Oncol 21 (2003): 2299-304. [PMID: 12805330]
3	Zangari M, Siegel E, Barlogie B, et al "Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy." Blood 100 (2002): 1168-71. [PMID: 12149193]
4	Product Information. Cyklokapron (tranexamic acid). Pharmacia and Upjohn, Kalamazoo, MI.
5	van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR "The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study." BMJ 339 (2009): b2921.[PMID: 19679614]
6	Gomes MP, Deitcher SR "Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review." Arch Intern Med 164 (2004): 1965-76.[PMID: 15477430]
7	Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4. [PMID: 4381950]
8	Product Information. Dymelor (acetohexamide) Lilly, Eli and Company, Indianapolis, IN.
9	Product Information. Thorazine (chlorpromazine). SmithKline Beecham, Philadelphia, PA.
10	Cerner Multum, Inc. "Australian Product Information.".
11	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12	Notelovitz M "Oral contraception and coagulation." Clin Obstet Gynecol 28 (1985): 73-83. [PMID: 3987135]
13	Stangel JJ, Innerfield I, Reyniak JV, Stone ML "The effect of conjugated estrogens on coagulability in menopausal women." Obstet Gynecol 49 (1977): 314-6. [PMID: 190571]
14	von Kaulla E, Droegemueller W, von Kaulla KN "Conjugated estrogens and hypercoagulability." Am J Obstet Gynecol 122 (1975): 688-92. [PMID: 15850603]
15	Legler UF, Benet LZ "Marked alterations in dose-dependent prednisolone kinetics in women taking oral contraceptives." Clin Pharmacol Ther 39 (1986): 425-9
16	Meffin PJ, Wing LM, Sallustio BC, Brooks PM "Alterations in prednisolone as a result of oral contraceptive use and dose." Br J Clin Pharmacol 17 (1984): 655-64
17	Frey BM, Schaad HJ, Frey FJ "Pharmacokinetic interaction of contraceptive steroids with prednisone and prednisolone." Eur J Clin Pharmacol 26 (1984): 505-11
18	Product Information. Vectical (calcitriol topical). Galderma Laboratories Inc, Cranbury, NJ.
19	Product Information. Dovonex (calcipotriene). Westwood Squibb Pharmaceutical Corporation, Eatontown, NJ.
20	Product Information. Aromasin (exemestane) Pharmacia &amp Upjohn, Kalamazoo, MI.
21	Product Information. Femara (letrozole). Novartis Pharmaceuticals, East Hanover, NJ.
22	Product Information. Arimidex (anastrozole). Zeneca Pharmaceuticals, Wilmington, DE.
23	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
24	Arafah BM "Increased need for thyroxine in women with hypothyroidism during estrogen therapy." N Engl J Med 344 (2001): 1743-9. [PMID: 11396440]
25	Product Information. Synthroid (levothyroxine). Abbott Pharmaceutical, Abbott Park, IL.
26	Utiger RD "Estrogen, thyroxine binding in serum, and thyroxine therapy." N Engl J Med 344 (2001): 1784-5. [PMID: 11396448]
27	Wilbur K, Ensom MHH "Pharmacokinetic drug interactions between oral contraceptives and second-generation anticonvulsants." Clin Pharmacokinet 38 (2000): 355-65. [PMID: 10803456]
28	Ohman I, Vitols S, Tomson T "Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation." Epilepsia 41 (2000): 706-13
29	Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol. 2006 Feb;61(2):191-9.
30	Chetkowski RJ, Meldrum DR, Steingold KA, et al. "Biologic effects of transdermal estradiol." N Engl J Med 314 (1986): 1615-20. [PMID: 3012339]
31	Irving S, Vadiveloo T, Leese GP "Drugs that interact with levothyroxine an observational study from the Thyroid Epidemiology, Audit and Research Study (TEARS)." Clin Endocrinol (Oxf) (2014):. [PMID: 25040647]
32	Product Information. Nextstellis (drospirenone-estetrol). Mayne Pharma, Greenville, NC.
33	Koch-Weser J, Sellers EM "Drug interactions with coumarin anticoagulants (second of two parts)." N Engl J Med 285 (1971): 547-58. [PMID: 4397794]
34	Ku LL, Ward CO, Durgin SJ "A clinical study of drug interaction and anticoagulant therapy." Drug Intell Clin Pharm 4 (1970): 300-6.
35	Meade TW "Oral contraceptives, clotting factors, and thrombosis." Am J Obstet Gynecol 142 (1982): 758-61. [PMID: 6801980]
36	Schrogie JJ, Solomon HM, Zieve PD "Effect of oral contraceptives on vitamin K-dependent clotting activity." Clin Pharmacol Ther 8 (1967): 670-5. [PMID: 4167917]
37	Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
38	Somani SM, Khurana RC "Mechanism of estrogen-imipramine interaction." JAMA 223 (1973): 560. [PMID: 4739153]
39	Eichling PS, Sahni J. Menopause related sleep disorders. J Clin Sleep Med. 2005 Jul 15;1(3):291-300.
40	Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
41	Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
42	Product Information. Vitrase (hyaluronidase). Bausch and Lomb, Rochester, NY.

Details of Drug

Details of Drug

Cite MecDDI

About MecDDI

Correspondence